Callio Therapeutics
Clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) that pair two synergistic payloads to overcome the resistance limiting single-payload ADCs; lead candidate CLIO-8221 combines exatecan with an ATR inhibitor against HER2-expressing tumors and is in Phase 1/2 in the US and Australia.
Headquarters
Seattle, USA / San Diego, USA / Singapore
Year Founded
2025
Founders
Piers Ingram, Jerome Boyd-Kirkup (Hummingbird Bioscience spinout); Zachary Hornby (CEO since 2026)
Country
Singapore
Financial Information
Funding Stage
Series A
Recent Funding
$187M
Funding By
Frazier Life Sciences, Jeito Capital, Novo Holdings, Omega Funds, ClavystBio, EDBI
Core Technology
Dual-payload ADC platform (site-specific linker with rationally paired payload combinations)
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: Phase 1/2 CLIO-8221 in HER2-expressing solid tumors (NCT07300943)
- Patents / IP Status: Proprietary linker-payload IP, spun out of Hummingbird Bioscience
Partnerships
Pharma Collaborations
Hummingbird Bioscience (asset spinout); planned expansion into China
Academic / Hospital Tie-ups
US and Australian clinical trial sites
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Two synergistic payloads per antibody to block the escape pathways that limit single-payload ADCs